Adverse events · All patients with cancer who are receiving treatment
2 findings from 1 review
Adverse events reported narratively: one study did not report adverse events (Askarifar 2015); another reported no serious adverse events (Toro 2013); the remaining two reported low rates of shooting pain from the…
3 studies
GRADE not reported
Adverse events reported narratively (not meta-analysed): one study reported no adverse effects (Katranci 2012); the other four 5FU studies reported low rates of very minor adverse events (headache, chills,…
5 studies · 444 participants
GRADE not reported
Adverse events: hyponatraemia · children with severe dehydration due to diarrhoea
Balanced crystalloid solutions showed no clear difference in adverse events: hyponatraemia compared with 0.9% saline (low certainty).
1 finding from 1 review
RR 1.41 [0.96, 2.07]
Studies not reported
Low
Adverse events · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events grade 3 to 5 Range of · patients with non‐muscle invasive bladder cancer
Gemcitabine showed no clear difference in grade III–V adverse events compared with saline (low certainty).
1 finding from 1 review
Adverse events: grade 1 to 2 · patients with non‐muscle invasive bladder cancer
Gemcitabine showed no clear difference in grade I or II adverse events compared with saline (low certainty).
1 finding from 1 review
Adverse events ‐ not measured · susceptible people exposed to rubella
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events after 4 weeks of · participants with chronic leg ulcers
1 finding from 1 review
Serious adverse events (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Adverse events: all grades · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in adverse events of any grade (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… led to higher adverse events at grade 3 or 4 (by day 28) compared with saline placebo; GRADE not reported.
1 finding from 1 review
OR 4
3 participants
GRADE not reported
Grades 3 and 4 adverse events · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma probably leads to higher adverse events at grades 3 to 4 up to 28 days compared with saline placebo (moderate certainty).
1 finding from 1 review
RR 4.09 [1.39, 12.01]
Studies not reported
Moderate
Primary outcome 3: Adverse events · ulceration and other skin changes caused by nerve damage in leprosy
1 finding from 1 review
Serious adverse events: life‐threatening/ hospitalisation · adults with surgical wounds
1 finding from 1 review
Significant adverse events (seizures, thromboembolism) within 24 hours of surgery) · adults and children with chronic rhinosinusitis with or without nasal polyps
Tranexamic acid showed no clear difference in significant adverse events (seizures, thromboembolism) within 24… compared with placebo (saline solution or sterile water) (moderate certainty).
1 finding from 1 review
Changes in microbiome in oral cavity, nasal cavity, oro- or nasopharynx · Patients without suspected or confirmed COVID-19 infection undergoing aerosol-generating procedures (AGPs), and the healthcare workers…
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events: all grades · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in adverse events of any grade up to 28 days (data only available for… compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.98 [0.81, 1.18]
Studies not reported
Low
Serious adverse events up to day 28 (data available only as a composite of serious adverse events or death up to day 28) · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in serious adverse events up to day 28 (data available only as a… compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.72 [0.45, 1.14]
Studies not reported
Low
Adverse events (common reactions to aromatherapy include skin rashes, dyspnoea, headache, cardiac arrhythmias, hypotension, hypertension or dizziness) · adults and children having any type of surgical procedure under general anaesthesia, regional anaesthesia or sedation, as hospital…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found